Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation.
Neither IGC, the American College of Rheumatology, nor the authors endorse any product or
service associated with the distributor of this clinical reference tool.
Abbreviations
ACR, American College of Rheumatolog y; AFB, Acid-fast bacilli; CDC, Centers
for Disease Control and Prevention; CHF, Congestive Heart Failure; COBRA,
Combinatietherapie Bij Reumatoide Artritis; DAS, Disease Activity Score; DMARD,
Disease Modifying Antirheumatic Drug (includes hydroxychloroquine, leflunomide,
MTX); EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment
Questionnaire Disability Index; HBV, Hepatitis B virus; HCV, Hepatitis C virus;
IGRA, Interferon-gamma release assay; MTX, methotrexate; NYHA, New York Heart
Association; RA, rheumatoid arthritis; TNF, Tumor Necrosis Factor, non-TNF biologic,
non-Tumor Necrosis Factor biologic; TNFi, Tumor Necrosis Factor inhibitor; TST,
tuberculin skin test
Source
Singh JA, Saag KG, Bridges Jr. SL, et al. Guideline for the Treatment of Rheumatoid
Arthritis. Arthritis Care Res (Hoboken). 2015 Nov 6. doi: 10.1002/acr.22783. [Epub
ahead of print]
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2015 All rights reserved
ACRRA15122a
